GF Fund Management CO. LTD. Makes New $841,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

GF Fund Management CO. LTD. acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 4,278 shares of the medical research company's stock, valued at approximately $841,000.

Several other institutional investors and hedge funds have also recently modified their holdings of IQV. Vanguard Group Inc. lifted its holdings in shares of IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after buying an additional 712,958 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. lifted its position in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after purchasing an additional 59,426 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 1.5%

NYSE:IQV traded up $2.15 on Thursday, reaching $140.93. 2,250,153 shares of the company's stock were exchanged, compared to its average volume of 1,570,286. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $24.38 billion, a price-to-earnings ratio of 18.79, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The business has a fifty day moving average of $152.52 and a 200-day moving average of $181.96. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on IQV. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Truist Financial lowered their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Finally, Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.